



H1 2025 results

July 16, 2025


Forward-looking statements

This presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management's current intentions, beliefs or expectations relating to, among other things, Ontex's future results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. By their nature, forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results or future events to differ materially from those expressed or implied thereby. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.

Forward-looking statements contained in this presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on any such forward-looking statements, which speak only as of the date of this presentation.

↗ Lower-than-expected volumes in H1 impacted profitability and cash generation


H1 2025



↗ Soft customer demand in baby care led to lower revenue

H1 revenue YOY

(in €M)




- > Negative sales price carry-over from 2024 actions
- > Baby care down 10% LFL, reflecting lower customer demand
 - Retailer brand market demand down by high single digit in Europe and North America due to soft overall demand and intense promotional A-brand activity
 - Ontex impact magnified by geographical mix and customer destocking
 - Contract gains mainly in North America
 - Temporary supply chain disruptions for specific products in Europe
- > Feminine care down 5% LFL, due to supply chain disruptions
 - Segovia plant outage
 - Unavailability of packaging materials
- > Adult care up 3% LFL, on sustained growing demand, while lower than market due to capacity ramp-up

Revenue decline explains the lower adj. EBITDA

Cost transformation program almost fully mitigates cost increases


H1 adj. EBITDA YOY
(in €M)



- > Direct impact of price carry-over
- > Volume/mix reduction leading to a significant relative impact on EBITDA incl. lower fixed cost absorption
- > Solid net savings delivery by cost transformation program, despite lower volumes, thanks to further implementation of cost transformation actions
- > Raw materials costs up by 4%, especially for fluff
- > Other operating costs up by 8%
 - Half linked to inflation of salaries and services
 - Half linked to temporary costs
 - Efforts made to compensate supply chain disruptions
 - Planned US volume ramp-up anticipation
 - US tariff mitigation costs
- > SG&A costs re-adjusted to lower profitability level

↗ Customer demand deteriorated further in Q2, magnified by temporary increases in raw material and operating costs

Q1 & Q2 adj. EBITDA YOY
(in €M)



> Market environment deteriorated in Q2


- Customer demand deteriorated further, magnified by some customer destocking and supply chain disruptions
- Lower volumes led to lower fixed cost absorption, increasing negative impact on EBITDA
- Raw materials costs significantly up in Q2 (improving in H2)
- Other operating costs increased more due to additional temporary inefficiencies and costs of mitigation actions

> But also showed some bright spots

- Negative price carry-over in Q1 fading out in Q2
- Better contribution from net operating savings, despite lower volumes, thanks to further implementation of cost transformation actions

➤ Negative FCF with lower EBITDA and continued transformation Compensated by divestment proceeds

2025 H1 cash impact on net debt
(in €M)




- > €(45)M capex at ~5% of Core revenue, temporarily higher due to cost transformation and business growth program
- > €(23)M one-off cash costs related mainly to Belgian restructuring
- > Lower use of factoring
- > €101M M&A proceeds, mostly from Brazil divestment, incl. escrow
- > €(11)M buy-back of 1.5M shares, to cover for LTI plans

↗ Leverage maintained below 3x

Net debt evolution

(in €M)




- > Net debt reduced from €(612)M to €(552)M
- > Leverage increased slightly to 2.7x due to lower LTM EBITDA, remains comfortably below 3.5x covenant^[2] threshold
- > Gross debt reduced to €(698)M and secured for next 5 years
 - €400M (5.25%) bond replaces old €580M (3.50%) bond
 - RCF utilized for 2/3rd, leaving sufficient liquidity including cash

[1] Other consists mainly of non-cash changes, e.g. the reduction in leases following the divestment in Brazil


[2] 3.5x leverage covenant on RCF

↗ Adverse events impacting H1 to ease in H2



↗ H2 adj. EBITDA expected to benefit both from volume growth and net cost improvement

2025 H1 to H2 adj. EBITDA bridge
(in €M)



- > Sales price expected largely stable
- > Volume-driven revenue growth of 5-9% LFL, positively impacting adj. EBITDA, and boosted by fixed cost absorption effect
 - Customer destocking over
 - New contracts kicking in, in North America and Europe
 - Supply chain disruptions solved
 - New capacity in high-growth categories
- > Continuous improvement delivered by cost transformation program, supported by higher volumes
- > Easing of raw material prices, incl. USD transactional effect
- > Exceptional costs linked to supply chain mitigation efforts and US tariffs solved, offsetting further inflation of salaries and services
- > SG&A costs largely stable
- > Net translational forex effects to be largely neutral

Full year outlook adjusted post H1

Revenue

down LFL by
low single digit

vs +3% - +5% LFL
previously

H1

-4%

H2

-2% - +2%

Adj. EBITDA

€200 - 210M

vs €232 - 238M
previously

H1

€86M

H2

€114 - 124M

Free
cash flow

~€0M

vs remaining strong
previously

H1

€(40)M

H2

~€40M

Leverage

~2.5x

vs <2.5x
previously

06/25

2.7x

12/25

~2.5x

➤ Confirming our strategy as we build solid foundations for the future

Structural improvement journey

Completion status (July 2025)

+ Healthier balance sheet	100%
> Refinancing completed in H1 2025	
> Divestments from Emerging Markets	
+ Robust innovation pipeline	~70%
+ Significant step up in operational efficiency	~50%
+ Fast growth in North America	~70%
+ Lean, performance-driven organization	~60%

**Importance to
keep executing
our strategy to
create long-
term value**

Q&A



Ontex

Here for you.